Sanofi (NASDAQ:SNY) Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp boosted its position in Sanofi (NASDAQ:SNY) by 18.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 662,762 shares of the company’s stock after purchasing an additional 101,726 shares during the quarter. Van ECK Associates Corp’s holdings in Sanofi were worth $31,965,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Creative Planning raised its position in shares of Sanofi by 18.0% during the 3rd quarter. Creative Planning now owns 220,763 shares of the company’s stock worth $12,723,000 after buying an additional 33,728 shares in the last quarter. Asset Dedication LLC raised its position in shares of Sanofi by 284.1% during the 3rd quarter. Asset Dedication LLC now owns 3,902 shares of the company’s stock worth $225,000 after buying an additional 2,886 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Sanofi by 15.2% during the 3rd quarter. Global Retirement Partners LLC now owns 6,315 shares of the company’s stock worth $364,000 after buying an additional 834 shares in the last quarter. Bleakley Financial Group LLC raised its position in shares of Sanofi by 3.6% during the 3rd quarter. Bleakley Financial Group LLC now owns 120,631 shares of the company’s stock worth $6,952,000 after buying an additional 4,190 shares in the last quarter. Finally, Cardinal Capital Management raised its position in shares of Sanofi by 1.4% during the 3rd quarter. Cardinal Capital Management now owns 67,523 shares of the company’s stock worth $3,891,000 after buying an additional 938 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Up 0.9 %

NASDAQ SNY opened at $54.50 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The company’s 50 day simple moving average is $50.30 and its 200 day simple moving average is $52.44. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a market capitalization of $138.31 billion, a P/E ratio of 21.89, a PEG ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on SNY shares. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.